Breaking News

Amarantus Completes Acquisition of ESS From Lonza

Now has full ownership of Cutanogen Corporation

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amarantus BioScience Holdings Inc., a biotechnology company focused on developing therapeutic and diagnostic products for diseases in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, has completed the acquisition of Cutanogen Corporation from Lonza Walkersville Inc., a subsidiary of Lonza Group Ltd. Cutanogen has an exclusive worldwide license to intellectual property rights associated with Engineered Skin Substitute (ESS), an autologous full thickness skin replace...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters